Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 Antibody Responses in End-Stage Renal Disease Patients After COVID-19 Vaccination
TCTR20210510009Not yet recruiting
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
- Start
- May 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronavirus disease 2019 (COVID-19), sponsored by Bamrasnaradura Infectious Diseases Institute. Primary endpoint: SARS-CoV-2 antibody response. Planned start May 2021; status: not yet recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210510009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210510009.